Proton Pump Inhibitors (PPIs) are potent suppressors of gastric acid and are the mainstay in the management of a wide range of conditions affecting the upper gastrointestinal tract. 1,2 PPIs are routinely available as oral and intravenous dosage forms. 2 They are commonly prescribed in the palliative demographic for the prophylaxis of gastrointestinal bleeding, prevention of re-bleeding, and for the symptomatic management of both dyspepsia, and reflux. 3 Yet in the palliative demographic, swallowing difficulties are common, particularly towards the end-of-life. 3 Dysphagia often precludes the use of PPIs in dying patients, and the placement of an